Avidity biosciences joins with patients, caregivers and healthcare providers globally to support world facioscapulohumeral muscular dystrophy (fshd) day

Avidity is currently enrolling participants in the phase 1/2 fortitude™ study of aoc 1020 for the treatment of fshd company anticipates data from a preliminary assessment in half of the participants in the fortitude study in 1h 2024 san diego , june 20, 2023 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), joins with the global community of patients, caregivers, and healthcare providers in support of world facioscapulohumeral muscular dystrophy (fshd) day. fshd is a serious, rare, hereditary muscle-weakening condition marked by life-long, progressive loss of muscle function that causes significant pain, fatigue, and disability.
RNA Ratings Summary
RNA Quant Ranking